ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer
Data from the CheckMate-920 study on the safety and effectiveness [...]
Pembrolizumab as first-line treatment for kidney cancer
The recent phase II KEYNOTE-427 study investigated the efficacy and [...]
Top stories from 2020 for kidney cancer
Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the [...]
2020 top stories in kidney cancer
This article summarises the key breakthroughs in the treatment of [...]
Cabozantinib plus atezolizumab for non-clear cell kidney cancer
In this video interview, Dr Monty Pal from the City [...]
Lenvatinib plus everolimus for non clear cell kidney cancer
Treating non-clear cell renal cell carcinoma (RCC) is challenging because [...]
Differences in survival with tremelimumab due to different types of kidney cancer
Most people have a type of kidney cancer called clear [...]
Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma
In this video interview with Dr Monty Pal from the [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
Safety and efficacy of nivolumab for non-clear cell kidney cancer
Nivolumab alone and in combination with ipilimumab is used for the treatment of [...]
